Ibalizumab significantly reduces viral load in patients with multidrug-resistant (MDR) HIV-1, according to results from a single-arm, open-label phase 3 study. "Ibalizumab will provide an additional opportunity to achieve viral suppression for patients who have exhausted most currently available treatment options," Dr. Stanley Lewis from TaiMed Biologics, in Irvine, California reported.
All news from Venereology
Across the globe, HIV prevalence among sex workers is estimated to be as much as 12 times that of the general population. In Kenya, HIV prevalence among sex workers is about 30% compared to 5.4% in the general population.
A number of studies have found that bringing HIV self-testing to potential users can increase HIV testing rates among key populations such as sex workers.
A new study has shown that genital warts may promote HIV sexual transmission and, in turn, their treatment and prevention could help decrease the spread of the disease. These findings appear in the Journal of Infectious Diseases.
Adolescents who receive recommended vaccinations, including for human papillomavirus, have no increased risk of primary ovarian insufficiency, also known as premature menopause, according to a Kaiser Permanente study published in Pediatrics.
Infection rates of high-risk human papillomavirus (HR-HPV) oral infection in England are lower than expected, compared to previous US studies.
Girls and young women who initiate the human papillomavirus (HPV) vaccine series between ages 15 and 20 years and receive all three doses are adequately protected against cancers caused by HPV infection, new data suggest. Catch-up vaccination among those ages 21 to 26 does not provide the same benefit, however.
Extended-release naltrexone — an injection that decreases heavy drinking in the general population when taken in conjunction with counseling — appears to help HIV-positive individuals reduce their number of heavy drinking days too, say Yale researchers. This study was published online in AIDS and Behavior.
Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV—the virus that causes AIDS—and the hepatitis C virus.
The study revealed that two genes—CMPK2 and BCLG, are selectively activated in the presence of type 1 interferon, a drug once used as the first line of treatment against hepatitis C. Results of the study were published online in Science Advances.
Without treatment, an HIV-infected child is at greater risk of disease progression to AIDS than an adult. Initiation of early treatment in infants shows an undeniable clinical benefit by reducing the risk of death in early childhood. It may also be accompanied by a significant reduction of the viral reservoir (the amount of total viral DNA present in the immune cells of patients), which could promote the accumulation of conditions required for remission.
Patient associations lauded an EU decision to allow the sale of generic versions of Truvada, an anti-retroviral medicine used by those diagnosed HIV-positive, the virus causing AIDS.
Good news in the battle against the growing threat of drug-resistant “super gonorrhea”: Researchers at the University of Virginia School of Medicine and their collaborators in the United Kingdom have discovered a new way that the bacteria that cause gonorrhea resist the body’s immune defenses. Scientists can use this knowledge to develop vaccines or empower our immune system to take down a sexually transmitted bug that has already conquered most antibiotics.
The initial findings of the ANRS CLEAC study coordinated by Pierre Frange (Hôpital Necker – AP-HP), help define the immunological and virological benefits of early antiretroviral therapy in HIV-infected children living in France.
The results of this study will be presented by Florence Buseyne (Oncogenic Virus Epidemiology & Pathophysiology Team – Institut Pasteur) this Wednesday, 25 July at the 22nd International AIDS Conference (AIDS 2018) being held in Amsterdam from 23 to 26 July 2018.